Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow WHWK by emailGet an email when WHWK pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about WHWK, unsubscribe in one click. Privacy
📣 What WHWK Says Is Next
1H 2027 · “HWK-007 and HWK-016 – ongoing recruitment into Phase 1 trials, with initial results expected in 1H 2027.”
Company press release, Aug 6, 2026 · SEC filing
first half of 2027 · “Whitehawk’s Clinical Pipeline Phase 1 trials for PTK7-directed HWK-007 and MUC16-directed HWK-016 are advancing through dose-escalation, with data expected in the first half of 2027.”
Company press release, May 21, 2026 · SEC filing
1H 2027 · ““We remain focused on high quality execution as we build toward initial data anticipated in 1H 2027, with the goal of delivering meaningful benefits for patients.” Q1 2026 and Recent Operational Highlights:”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full WHWK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for WHWK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.